Advanced search
Publication Cover
Expert Review of Neurotherapeutics Volume 11, 2011 - Issue 10
Submit an article Journal homepage
393
Views
29
CrossRef citations to date
0
Altmetric
Special Report

Efficacy and tolerability of ramelteon in a double-blind, placebo-controlled, crossover study in Japanese patients with chronic primary insomnia

Masako Kohsaka Ishikane Hospital, Hokkaido, Japan; Ishikane Hospital, Hokkaido, Japan
,
Takashi Kanemura Department of Sleep Medicine, Shiga University of Medical Science, Shiga, Japan; Department of Sleep Medicine, Shiga University of Medical Science, Shiga, Japan
,
Mitsutaka Taniguchi Sleep Medical Center, Osaka Kaisei Hospital, Osaka, Japan; Sleep Medical Center, Osaka Kaisei Hospital, Osaka, Japan
,
Hiroo Kuwahara Department of Neuropsychiatry, Kurume University School of Medicine, Fukuoka, Japan; Department of Neuropsychiatry, Kurume University School of Medicine, Fukuoka, Japan
,
Akira Mikami Osaka University Health Care Center, Osaka, Japan; Osaka University Health Care Center, Osaka, Japan
,
Kunihisa Kamikawa Takeda Pharmaceutical Company Limited, Osaka, Japan; Japan Development Center, Pharmaceutical Development Division, Takeda Pharmaceutical Company Limited, Osaka, Japan; Takeda Pharmaceutical Company Limited, Osaka, Japan; Japan Development Center, Pharmaceutical Development Division, Takeda Pharmaceutical Company Limited, Osaka, Japan
,
Hideki Uno Takeda Pharmaceutical Company Limited, Osaka, Japan; Japan Development Center, Pharmaceutical Development Division, Takeda Pharmaceutical Company Limited, Osaka, Japan; Takeda Pharmaceutical Company Limited, Osaka, Japan; Japan Development Center, Pharmaceutical Development Division, Takeda Pharmaceutical Company Limited, Osaka, Japan
,
Atsushi Ogawa Takeda Pharmaceutical Company Limited, Osaka, Japan; Japan Development Center, Pharmaceutical Development Division, Takeda Pharmaceutical Company Limited, Osaka, Japan;[email protected]
,
Mitsukuni Murasaki Institute of CNS Pharmacology, Kanagawa, Japan; Institute of CNS Pharmacology, Kanagawa, Japan
&
Yoshiro Sugita Osaka University Health Care Center, Osaka, Japan; Osaka University Health Care Center, Osaka, Japan
 show all
Pages 1389-1397 | Published online: 09 Jan 2014

References

  • Benca RM. Diagnosis and treatment of chronic insomnia: a review. Psychiatr. Serv.56, 332–343 (2005).
  • Roth T. Insomnia: definition, prevalence, etiology, and consequences. J. Clin. Sleep Med.3(5 Suppl.), S7–S10 (2007).
  • Kim K, Uchiyama M, Okawa M, Liu X, Ogihara R. An epidemiological study of insomnia among the Japanese general population. Sleep23, 41–47 (2000).
  • Buscemi N, Vandermeer B, Friesen C et al. The efficacy and safety of drug treatments for chronic insomnia in adults: a meta-analysis of RCTs. J. Gen. Intern. Med.22, 1335–1350 (2007).
  • Holbrook AM, Crowther R, Lotter A, Cheng C, King D. Meta-analysis of benzodiazepine use in the treatment of insomnia. Can. Med. Assoc. J.162, 225–233 (2000).
  • Ramakrishnan K, Scheid DC. Treatment options for insomnia. Am. Fam. Physician76, 517–526 (2007).
  • Doghramji K. Melatonin and its receptors: a new class of sleep-promoting agents. J. Clin. Sleep Med.3(5 Suppl.), S17–S23 (2007).
  • Kato K, Hirai K, Nishiyama K et al. Neurochemical properties of ramelteon (TAK-375), a selective MT1/MT2 receptor agonist. Neuropharmacology48, 301–310 (2005).
  • Reynoldson JN, Elliott E Sr, Nelson LA. Ramelteon: a novel approach in the treatment of insomnia. Ann. Pharmacother.42, 1262–1271 (2008).
  • Karim A, Tolbert D, Cao C. Disposition kinetics and tolerance of escalating single doses of ramelteon, a high affinity MT1 and MT2 melatonin receptor agonist indicated for treatment of insomnia. J. Clin. Pharmacol.46(2), 140–148 (2006).
  • Erman M, Seiden D, Zammit G, Sainati S, Zhang J. An efficacy, safety, and dose–response study of ramelteon in patients with chronic primary insomnia. Sleep Med.7, 17–24 (2006).
  • Mayer G, Wang-Weigand S, Roth-Schechter B, Lehmann R, Staner C, Partinen M. Efficacy and safety of 6-month nightly ramelteon administration in adults with chronic primary insomnia. Sleep32, 351–360 (2009).
  • Roth T, Seiden D, Sainati S, Wang-Weigand S, Zhang J, Zee P. Effects of ramelteon on patient-reported sleep latency in older adults with chronic insomnia. Sleep Med.7, 312–318 (2006).
  • Roth T, Seiden D, Wang-Weigand S, Zhang J. A 2-night, 3-period, crossover study of ramelteon’s efficacy and safety in older adults with chronic insomnia. Curr. Med. Res. Opin.23, 1005–1014 (2007).
  • Hirai K, Kita M, Ohta H et al. Ramelteon (TAK-375) accelerates reentrainment of circadian rhythm after a phase advance of the light–dark cycle in rats. J. Biol. Rhythms20, 27–37 (2005).
  • Richardson GS, Zee PC, Wang-Weigand S, Rodriguez L, Peng X. Circadian phase-shifting effects of repeated ramelteon administration in healthy adults. J. Clin. Sleep Med.4, 456–461 (2008).
  • Zee PC, Wang-Weigand S, Wright KP Jr, Peng X, Roth T. Effects of ramelteon on insomnia symptoms induced by rapid, eastward travel. Sleep Med.11, 525–533 (2010).
  • American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th Edition, Text Revision (DSM-IV-TR). American Psychiatric Association, VA, USA (2000).
  • Zammit G, Erman M, Wang-Weigand S, Sainati S, Zhang J, Roth T. Evaluation of the efficacy and safety of ramelteon in subjects with chronic insomnia. J. Clin. Sleep Med.3, 495–504 (2007).
  • Johnson MW, Suess PE, Griffiths RR. Ramelteon: a novel hypnotic lacking abuse liability and sedative adverse effects. Arch. Gen. Psychiatry63, 1149–1157 (2006).
  • Lewy A, Emens J, Jackman A, Yuhas K. Circadian uses of melatonin in humans. Chronobiol. Int.23, 403–412 (2006).
  • Wilson SJ, Nutt DJ, Alford C et al. British Association for Psychopharmacology consensus statement on evidence-based treatment for insomnia, parainsomnias and circadian rhythm disorders. J. Psychopharmacol.24(11), 1577–1600 (2010).
  • Estivill E, Bové A, García-Borreguero D et al. Consensus on drug treatment, definition and diagnosis for insomnia. Clin. Drug. Investig.23(6), 351–385 (2003).

Website

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.